Notable companies
The most notable companies in this group are ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Moderna (NASDAQ:MRNA).
Industry description
The investment seeks to provide capital appreciation.
Under normal circumstances, the fund invests substantially all (at least 80%) of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. It may invest to a significant extent in the securities of Biotechnology Companies that have small to mid-sized capitalizations. The fund is non-diversified.
Market Cap
The average market capitalization across the Rydex Biotechnology Inv MF is 115.18B. The market cap for tickers in the group ranges from 9.53B to 389.72B. ABBV holds the highest valuation in this group at 389.72B. The lowest valued company is MRNA at 9.53B.
Volume
The average weekly volume growth across all stocks in the Rydex Biotechnology Inv MF was -57%. For the same stocks of the MF, the average monthly volume growth was -16% and the average quarterly volume growth was 14%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Valuation Rating: 50
P/E Growth Rating: 68
Price Growth Rating: 56
SMR Rating: 46
Profit Risk Rating: 59
Seasonality Score: -19 (-100 ... +100)